This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wängberg, B. Articles by Ahlman, H. Search for Related Content PubMed PubMed Citation Articles by Wängberg, B. Articles by Ahlman, H.

Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumors

Departments of Surgery, Pathology, Radiation Physics, and Nuclear Medicine, Sahlgren University Hospital, Göteborg, Sweden

Correspondence: Håkan Ahlman, M.D., Department of Surgery, Sahlgren University Hospital, S-413 45 Göteborg, Sweden. Telephone: +46-31-601778; Fax: +46-31-82-57-29.

The expression of somatostatin receptors in neuroendocrine tumors has facilitated the diagnosis and surgical treatment of patients with these tumors. After injection of a radiolabeled long-acting somatostatin analog, ¹¹¹In-octreotide, scintigraphic tumor imaging can be performed as well as intraoperative tumor localization. During localization studies very high ¹¹¹In concentration values were found in tumor tissues versus normal tissues, especially in carcinoid tumors and endocrine pancreatic tumors. Studies on such tumors in cell culture further indicated internalization of ¹¹¹In into tumor cells, which is a prerequisite for a radiobiological effect from short range Auger and conversion electrons. Attempts to systemic radionuclide therapy via somatostatin receptors in patients with neuroendocrine tumors have been initiated.

Key Words. Neuroendocrine tumors • Somatostatin receptors • Nuclear medicine • Radiation therapy

This article has been cited by other articles:

				A. Schmitt, P. Bernhardt, O. Nilsson, H. Ahlman, L. Kolby, H. R. Maecke, and E. Forssell-Aronsson Radiation Therapy of Small Cell Lung Cancer with 177Lu-DOTA-Tyr3-Octreotate in an Animal Model J. Nucl. Med., September 1, 2004; 45(9): 1542 - 1548. [Abstract] [Full Text] [PDF]

				M. Lubberink, V. Tolmachev, C. Widstrom, A. Bruskin, H. Lundqvist, and J.-E. Westlin 110mIn-DTPA-D-Phe1-Octreotide for Imaging of Neuroendocrine Tumors with PET J. Nucl. Med., October 1, 2002; 43(10): 1391 - 1397. [Abstract] [Full Text] [PDF]

				L. Kolby, P. Bernhardt, H. Ahlman, B. Wangberg, V. Johanson, A. Wigander, E. Forssell-Aronsson, S. Karlsson, B. Ahren, G. Stenman, et al. A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake Am. J. Pathol., February 1, 2001; 158(2): 745 - 755. [Abstract] [Full Text] [PDF]